Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA

T. Tagawa, M. Manvell, N. Brown, M. Keller, E. Perouzel, Karl D Murray, R. P. Harbottle, M. Tecle, F. Booy, M. C. Brahimi-Horn, C. Coutelle, N. R. Lemoine, E. W F W Alton, A. D. Miller

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Liposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the μ (mu) peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 ± 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80°C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 μg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG5000 (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.

Original languageEnglish (US)
Pages (from-to)564-576
Number of pages13
JournalGene Therapy
Volume9
Issue number9
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

DNA Viruses
Adenoviridae
Liposomes
Nanoparticles
Plasmids
Peptides
DNA
Transfection
Gene Expression
Lung
Nuclear Envelope
Endocytosis

Keywords

  • Adenovirus
  • Cationic lipids
  • Cationic liposomes
  • mu peptide
  • Non-viral gene therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA. / Tagawa, T.; Manvell, M.; Brown, N.; Keller, M.; Perouzel, E.; Murray, Karl D; Harbottle, R. P.; Tecle, M.; Booy, F.; Brahimi-Horn, M. C.; Coutelle, C.; Lemoine, N. R.; Alton, E. W F W; Miller, A. D.

In: Gene Therapy, Vol. 9, No. 9, 2002, p. 564-576.

Research output: Contribution to journalArticle

Tagawa, T, Manvell, M, Brown, N, Keller, M, Perouzel, E, Murray, KD, Harbottle, RP, Tecle, M, Booy, F, Brahimi-Horn, MC, Coutelle, C, Lemoine, NR, Alton, EWFW & Miller, AD 2002, 'Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA', Gene Therapy, vol. 9, no. 9, pp. 564-576. https://doi.org/10.1038/sj.gt.3301686
Tagawa, T. ; Manvell, M. ; Brown, N. ; Keller, M. ; Perouzel, E. ; Murray, Karl D ; Harbottle, R. P. ; Tecle, M. ; Booy, F. ; Brahimi-Horn, M. C. ; Coutelle, C. ; Lemoine, N. R. ; Alton, E. W F W ; Miller, A. D. / Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA. In: Gene Therapy. 2002 ; Vol. 9, No. 9. pp. 564-576.
@article{ac3ef05e348b452798aaea51ed35f1a6,
title = "Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA",
abstract = "Liposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the μ (mu) peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 ± 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80°C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 μg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100{\%} serum) giving 15-25{\%} the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG5000 (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.",
keywords = "Adenovirus, Cationic lipids, Cationic liposomes, mu peptide, Non-viral gene therapy",
author = "T. Tagawa and M. Manvell and N. Brown and M. Keller and E. Perouzel and Murray, {Karl D} and Harbottle, {R. P.} and M. Tecle and F. Booy and Brahimi-Horn, {M. C.} and C. Coutelle and Lemoine, {N. R.} and Alton, {E. W F W} and Miller, {A. D.}",
year = "2002",
doi = "10.1038/sj.gt.3301686",
language = "English (US)",
volume = "9",
pages = "564--576",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide μ (mu) and plasmid DNA

AU - Tagawa, T.

AU - Manvell, M.

AU - Brown, N.

AU - Keller, M.

AU - Perouzel, E.

AU - Murray, Karl D

AU - Harbottle, R. P.

AU - Tecle, M.

AU - Booy, F.

AU - Brahimi-Horn, M. C.

AU - Coutelle, C.

AU - Lemoine, N. R.

AU - Alton, E. W F W

AU - Miller, A. D.

PY - 2002

Y1 - 2002

N2 - Liposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the μ (mu) peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 ± 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80°C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 μg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG5000 (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.

AB - Liposome:mu:DNA (LMD) is a ternary nucleic acid delivery system built around the μ (mu) peptide associated with the condensed core complex of the adenovirus. LMD is prepared by precondensing plasmid DNA (D) with mu peptide (M) in a 1:0.6 (w/w) ratio and then combining these mu:DNA (MD) complexes with extruded cationic liposomes (L) resulting in a final lipid:mu:DNA ratio of 12:0.6:1 (w/w/w). Correct buffer conditions, reagent concentrations and rates of mixing are all crucial to success. However, once optimal conditions are established, homogeneous LMD particles (120 ± 30 nm) will result that each appear to comprise an MD particle encapsulated within a cationic bilammellar liposome. LMD particles can be formulated reproducibly, they are amenable to long-term storage (>1 month) at -80°C and are stable to aggregation at a plasmid DNA concentration up to 5 mg/ml (15 mM nucleotide concentration). Furthermore, LMD transfections are significantly more time and dose efficient in vitro than cationic liposome-plasmid DNA (LD) transfections. Transfection times as short as 10 min and plasmid DNA doses as low as 0.001 μg/well result in significant gene expression. LMD transfections will also take place in the presence of biological fluids (eg up to 100% serum) giving 15-25% the level of gene expression observed in the absence of serum. Results from confocal microscopy experiments using fluorescent-labelled LMD particles suggest that endocytosis is not a significant barrier to LMD transfection, although the nuclear membrane still is. We also confirm that topical lung transfection in vivo by LMD is at least equal in absolute terms with transfection mediated by GL-67:DOPE:DMPE-PEG5000 (1:2:0.05 m/m/m), an accepted 'gold-standard' non-viral vector system for topical lung transfection, and is in fact at least six-fold more dose efficient. All these features make LMD an important new non-viral vector platform system from which to derive tailor-made non-viral delivery systems by a process of systematic modular upgrading.

KW - Adenovirus

KW - Cationic lipids

KW - Cationic liposomes

KW - mu peptide

KW - Non-viral gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0036265251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036265251&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301686

DO - 10.1038/sj.gt.3301686

M3 - Article

C2 - 11973632

AN - SCOPUS:0036265251

VL - 9

SP - 564

EP - 576

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 9

ER -